These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 16169076)
1. Opioids and differentiation in human cancer cells. Zagon IS; McLaughlin PJ Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076 [TBL] [Abstract][Full Text] [Related]
2. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Zagon IS; Rahn KA; McLaughlin PJ Neuropeptides; 2007 Dec; 41(6):441-52. PubMed ID: 17910895 [TBL] [Abstract][Full Text] [Related]
3. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Zagon IS; McLaughlin PJ Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586 [TBL] [Abstract][Full Text] [Related]
4. Opioids and the apoptotic pathway in human cancer cells. Zagon IS; McLaughlin PJ Neuropeptides; 2003 Apr; 37(2):79-88. PubMed ID: 12747939 [TBL] [Abstract][Full Text] [Related]
5. Reepithelialization of the human cornea is regulated by endogenous opioids. Zagon IS; Sassani JW; McLaughlin PJ Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604 [TBL] [Abstract][Full Text] [Related]
6. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium. Zagon IS; Ruth TB; McLaughlin PJ Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033 [TBL] [Abstract][Full Text] [Related]
8. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606 [TBL] [Abstract][Full Text] [Related]
9. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Donahue RN; McLaughlin PJ; Zagon IS Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817 [TBL] [Abstract][Full Text] [Related]
10. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Donahue RN; McLaughlin PJ; Zagon IS Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Zagon IS; Verderame MF; Hankins J; McLaughlin PJ Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915 [TBL] [Abstract][Full Text] [Related]
12. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460 [TBL] [Abstract][Full Text] [Related]
13. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration. McLaughlin PJ; Stack BC; Braine KM; Ruda JD; Zagon IS Int J Oncol; 2004 Jan; 24(1):227-32. PubMed ID: 14654962 [TBL] [Abstract][Full Text] [Related]
14. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cheng F; Zagon IS; Verderame MF; McLaughlin PJ Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995 [TBL] [Abstract][Full Text] [Related]
15. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor. McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840 [TBL] [Abstract][Full Text] [Related]
16. Opioid growth factor regulates the cell cycle of human neoplasias. Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512 [TBL] [Abstract][Full Text] [Related]
17. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy. Wang R; Zhang Y; Shan F Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891 [TBL] [Abstract][Full Text] [Related]
18. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis. Zagon IS; Wu Y; McLaughlin PJ J Invest Dermatol; 1996 Mar; 106(3):490-7. PubMed ID: 8648182 [TBL] [Abstract][Full Text] [Related]
19. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor. Zagon IS; Sassani JW; Kane ER; McLaughlin PJ Brain Res; 1997 Jun; 759(1):92-102. PubMed ID: 9219867 [TBL] [Abstract][Full Text] [Related]
20. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases. Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]